Acadian Asset Management
LAB icon

Acadian Asset Management’s Standard BioTools LAB Stock Holding History

Acadian Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,868
Closed -$19K – 1686
2023
Q4 		$19K Sell
8,868
-8,742
-50% -$18.7K ﹤0.01% 1593
2023
Q3 		$50K Buy
+17,610
New +$46.1K ﹤0.01% 1431
2021
Q1 		– Sell
-566,314
Closed -$3.4M – 2191
2020
Q4 		$3.4M Buy
566,314
+179,630
+46% +$1.18M 0.01% 608
2020
Q3 		$2.87M Sell
386,684
-945,502
-71% -$6.53M 0.01% 572
2020
Q2 		$5.34M Sell
1,332,186
-208,550
-14% -$726K 0.02% 470
2020
Q1 		$3.91M Sell
1,540,736
-146,945
-9% -$483K 0.02% 443
2019
Q4 		$5.87M Buy
1,687,681
+417,327
+33% +$1.47M 0.03% 407
2019
Q3 		$5.88M Buy
1,270,354
+215,610
+20% +$1.7M 0.03% 439
2019
Q2 		$13M Buy
1,054,744
+208,982
+25% +$2.66M 0.06% 243
2019
Q1 		$11.2M Buy
845,762
+307,013
+57% +$3.24M 0.05% 278
2018
Q4 		$4.64M Buy
538,749
+62,686
+13% +$488K 0.02% 387
2018
Q3 		$3.57M Buy
476,063
+49,972
+12% +$355K 0.01% 439
2018
Q2 		$2.54M Buy
426,091
+124,708
+41% +$711K 0.01% 504
2018
Q1 		$1.76M Buy
301,383
+154,678
+105% +$1.02M 0.01% 613
2017
Q4 		$864K Buy
146,705
+59,839
+69% +$328K ﹤0.01% 715
2017
Q3 		$438K Sell
86,866
-94,521
-52% -$397K ﹤0.01% 805
2017
Q2 		$732K Sell
181,387
-120,318
-40% -$570K ﹤0.01% 756
2017
Q1 		$1.72M Buy
301,705
+95,056
+46% +$602K 0.01% 658
2016
Q4 		$1.5M Sell
206,649
-37,809
-15% -$237K 0.01% 643
2016
Q3 		$1.96M Sell
244,458
-21,532
-8% -$198K 0.01% 551
2016
Q2 		$2.4M Sell
265,990
-161,066
-38% -$1.51M 0.01% 491
2016
Q1 		$3.45M Buy
427,056
+337,583
+377% +$2.43M 0.02% 458
2015
Q4 		$968K Buy
+89,473
New +$879K 0.01% 696

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Acadian Asset Management's LAB Position: Q1 2024 in Review

Acadian Asset Management sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 8,868 shares — an estimated $19K sold.

Acadian Asset Management first reported a position in LAB in Q4 2015 and held it in 23 quarters. The position peaked at $13M in Q2 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2024.

  • Acadian Asset Management reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 8,868 Standard BioTools shares in Q1 2024, an estimated $19K.
  • Acadian Asset Management first reported a position in Standard BioTools in Q4 2015 and held it in 23 quarters.
  • Acadian Asset Management's Standard BioTools position peaked at $13M in Q2 2019.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.